Abstract:The management of renal cell carcinoma (RCC) has been revolutionized over the past two decades with several practice-changing treatments. Treatment for RCC often requires a multimodal approach: Local treatment, such as surgery or ablation, is typically recommended for patients with localized tumors, while stage IV cancers often require both local and systemic therapy. The treatment of advanced RCC heavily relies on immunotherapy and targeted therapy, which are highly contingent upon histological subtypes. Despite years of research on biomarkers for RCC, the standard of care is to choose systemic therapy based on the risk profile according to the International Metastatic RCC Database Consortium and Memorial Sloan Kettering Cancer Centre models. However, many questions still need to be answered. Should we consider metastatic sites when deciding on treatment options for metastatic RCC? How do we choose between dual immunotherapy and combinations of immunotherapy and tyrosine kinase inhibitors? This review article aims to answer these unresolved questions surrounding the concept of personalized medicine.
biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
What problem does this paper attempt to address?
The problem that this paper attempts to solve is: In the treatment of metastatic renal cell carcinoma (mRCC), does the metastatic site have an important impact on treatment selection? Specifically, the author explored the impact of different metastatic sites (such as the lung, bone, brain, liver, etc.) on the treatment effect, and how to develop personalized treatment plans based on these metastatic sites.
### Core issues of the paper:
1. **Importance of metastatic sites**: Does the different metastatic sites in patients with metastatic renal cell carcinoma affect the treatment effect?
2. **Personalized treatment**: How to select the most appropriate treatment plan according to the metastatic site to achieve the best clinical effect?
### Background and motivation:
- **Epidemiology of renal cell carcinoma (RCC)**: Kidney cancer accounts for 5% of all cancers in men and 3% in women. According to GLOBOCAN 2020 data, RCC is the most common primary renal tumor, accounting for more than 85% of all renal tumors.
- **Prognosis of metastatic kidney cancer**: Approximately one - third of RCC patients have metastases at the time of diagnosis, and the five - year survival rate is only 12%.
- **Distribution of metastatic sites**: Lung metastases are the most common (45 - 80%), followed by bone (25 - 35%), lymph nodes (20 - 25%) and liver (18 - 20%). Brain metastases are relatively rare (4 - 11%).
- **Prognostic significance of metastatic sites**: There are significant differences in the prognosis of patients with different metastatic sites. For example, patients with only lung metastases have a higher survival rate, while patients with liver, bone, and brain metastases have a poorer prognosis.
### Research objectives:
- **Evaluate the impact of metastatic sites on treatment effects**: By reviewing existing clinical trial data, evaluate the impact of different metastatic sites on the effectiveness of systemic treatment.
- **Explore personalized treatment strategies**: Based on the characteristics of metastatic sites, propose personalized treatment recommendations to improve the survival rate and quality of life of patients.
### Main research contents:
- **Trends in systemic treatment**: Reviewed the history and development of RCC treatment, with a focus on discussing the application of immunotherapy and targeted therapy in mRCC.
- **Comparison of different treatment regimens**: Compared the effects of immune checkpoint inhibitor (ICI) monotherapy, ICI combination therapy (IO/IO), and ICI combined with tyrosine kinase inhibitor (TKI) combination therapy (IO/TKI).
- **Specific impacts of metastatic sites**: Analyzed in detail the impacts of different metastatic sites (such as bone, lung, brain, liver) on the treatment effect and proposed corresponding treatment recommendations.
### Conclusions:
- **Importance of metastatic sites**: Metastatic sites have a significant impact on the treatment effect of mRCC and need to be considered when formulating treatment plans.
- **Necessity of personalized treatment**: Selecting the most appropriate treatment plan according to the characteristics of different metastatic sites can improve the survival rate and quality of life of patients.
Through this review, the author aims to provide guidance for clinicians to help them develop more effective treatment plans based on metastatic sites when facing patients with metastatic renal cell carcinoma.